FLGT Fulgent Genetics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Fulgent Genetics, Inc. (FLGT) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 27, 2026, a 10-Q quarterly report filed on November 7, 2025, an 8-K current report filed on May 1, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Fulgent Genetics, Inc. (FLGT) (SEC CIK 1674930), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 7.01: Regulation FD Disclosure
- • Fulgent Genetics (FLGT) and Consonance Capital Partners announced dual transaction closings: PSA (Purchase and Sale Agreement) and APA (Asset Purchase Agreement)
- • Joint closing signals completion of a significant asset transaction with Consonance, a healthcare-focused investment firm
Item 2.01: Completion of Acquisition or Disposition of Assets
- • Combined cash consideration ~$56.9M ($13.5M for StrataDx equity + $43.4M for Bako assets), both deals closed March 17, 2026
- • APA covers dermatopathology, podiatric pathology, molecular diagnostics, and therapeutic products — direct bolt-on to Inform Diagnostics subsidiary
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings released Feb 27, 2026 — details in Exhibit 99.1
- • Covers fiscal year ended Dec 31, 2025 — full annual results included alongside quarterly figures
Item 7.01: Regulation FD Disclosure
- • Updated investor presentation published Feb 27, 2026, available on IR website and as Exhibit 99.2
- • Reg FD disclosure ensures material business updates reach all investors simultaneously — limits information asymmetry
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Fulgent Genetics, Inc. (FLGT) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | May 1, 2026 | — | — | — |
8-K | Mar 17, 2026 | — | Analysis | — |
8-K | Feb 27, 2026 | — | Analysis | — |
10-K | Feb 27, 2026 | Dec 31, 2025 | — | |
8-K | Dec 22, 2025 | — | — | |
10-Q | Nov 7, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 1, 2025 | Jun 30, 2025 | — | |
10-Q | May 2, 2025 | Mar 31, 2025 | — | |
10-Q | Nov 8, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 2, 2024 | Jun 30, 2024 | — | |
10-Q | May 3, 2024 | Mar 31, 2024 | — | |
10-K | Feb 28, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 3, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 4, 2023 | Jun 30, 2023 | — | |
10-Q | May 5, 2023 | Mar 31, 2023 | — | |
10-Q | Nov 7, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 4, 2022 | Jun 30, 2022 | — | |
10-Q | May 5, 2022 | Mar 31, 2022 | — | |
10-Q | Nov 9, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 10, 2021 | Jun 30, 2021 | — | |
10-Q | May 7, 2021 | Mar 31, 2021 | — | |
10-K | Mar 8, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 9, 2020 | Sep 30, 2020 | — | |
10-Q | Aug 5, 2020 | Jun 30, 2020 | — | |
10-Q | May 6, 2020 | Mar 31, 2020 | — |
Frequently Asked Questions
What are the latest FLGT SEC filings in 2026?
Fulgent Genetics, Inc. (FLGT) has filed a 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 7, 2025, an 8-K current report on May 1, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did FLGT file its most recent 10-K annual report?
Fulgent Genetics, Inc. (FLGT) filed its most recent 10-K annual report on February 27, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view FLGT 10-Q quarterly reports?
Fulgent Genetics, Inc. (FLGT)'s most recent 10-Q quarterly report was filed on November 7, 2025. SignalX displays every FLGT 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has FLGT filed recently?
Fulgent Genetics, Inc. (FLGT)'s most recent 8-K was filed on May 1, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find FLGT insider trading activity (Form 4)?
SignalX aggregates every FLGT Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does FLGT file with the SEC?
Fulgent Genetics, Inc. (FLGT) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new FLGT filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Fulgent Genetics, Inc. (FLGT).
What is FLGT's SEC CIK number?
Fulgent Genetics, Inc. (FLGT)'s SEC CIK (Central Index Key) number is 1674930. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1674930 to look up all FLGT filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find FLGT return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Fulgent Genetics, Inc. (FLGT) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Fulgent Genetics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 39+ filings.